All of the following statements about nasiritide are true except:
Ref:CMTD 2014/936;KDT 6/e p507 Nesiritide is a recombinant BNP It reduces vasodilation and natriuresis it has to be administered by i.v. route.
It is a BNP analogue
It can be used in decompensated CHF
It can be administered orally
It causes loss of Na+ in the urine
Cardiovascular system